Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Novavax $175.25 million convertible senior notes offering
The 5% convertible notes are due 2027
Terns Pharmaceuticals $86 million stock offering
The stock is listed on the Nasdaq Global Select Market
Coherus BioSciences $150 million at-the-market offering
The stock is listed on the Nasdaq Global Market
Priveterra Acquisition initial business combination with AEON Biopharma
We are advising Priveterra on the transaction
Illumina $1 billion notes offering
The investment-grade notes are due 2027
Prometheus Biosciences $500 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Lantheus Holdings $575 million convertible senior notes offering
The 2.625% convertible notes are due 2027
IVERIC bio $324.7 million stock offering
The shares are listed on the Nasdaq Global Select Market
Biodesix $40 million follow-on offering
The shares are listed on the Nasdaq Global Market